MegaPro Biomedical will be represented by general manager Dr. Jassy Wang, who will be heading for Suzhou to participate in the "Third China Pharmaceutical Innovation and Investment Conference" hosted by the China Pharmaceutical Promotion Association. A special roadshow will be held on September 19, 2018, 16:40-17:00, with the theme "A Nanomedicine for the Treatment of Iron Deficiency Anemia and as an MRI Imaging Agent", which mainly reports on the use of superparamagnetic iron oxide based on nanoparticles being successfully developed two indications: MPB-1514 iron deficiency anemia iron supplement and MPB-1523 developer - hepatocellular carcinoma, both of which have been approved by the US FDA clinical phase II trial.
About MPB-1514 Iron Deficiency Anemia Iron Supplements
MPB-1514 uses superparamagnetic iron oxide nanoparticles as basis and carries out modification and synthesis with polyethylene glycol by applying the PEGylation technology platform. It is highly efficient in macrophage phagocytosis and is not modified with sugars. As animal experiments have confirmed that it is less sensitizing, administration of high doses of MPB-1514 can allow the liver (which is responsible for hematopoiesis) to get sufficient iron, thereby improving the symptoms of iron deficiency anemia and reducing the frequency of patients having to go to the hospital.
About MPB-1523 Developer - Hepatocellular Carcinoma
MPB-1523 uses superparamagnetic iron oxide nanoparticles as basis and carries out modification and synthesis with polyethylene glycol by applying the PEGylation technology platform. It possesses the qualities of high nuclear magnetic relaxation and high efficiency of macrophage phagocytosis. These features can be applied to the visualization of tissues and organs rich in reticuloendothelial cells, such as the liver, spleen, and lymph nodes, for medical personnel to judge whether the patient has a benign or malignant tumor, and whether lymphatic metastasis or other diseases have occurred. In addition, it is free of problems such as the deposition of heavy metals in the human brain found in gadolinium-based developers on the market.
About MegaPro Biomedical
MegaPro Biomedical is a nano-drug development company branched from Taiwan Industrial Technology Research Institute, using nanoparticles and nano-cells as its core technology. At present, two indications of its nanoparticle products have been approved for phase two clinical trials by the U.S. FDA, which are the MPB-1514 iron deficiency anemia iron supplements and MPB-1523 MRI imaging agent-liver cancer, respectively. At the same time, the company is also using nano-cell technology to build an anti-cancer drug platform to accelerate the development of new forms of anti-cancer drugs. For other related company information, please visit http://www.megaprobio.com